All conditions

Vasculitis

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

583
Trials on record
142
Recruiting now
2
Australian sites
10
Phase 3 trials
1
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Vasculitis →

Get alerts when Vasculitis trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Vasculitis

Vasculitis is a condition where the immune system mistakenly attacks the walls of blood vessels, causing them to become inflamed and swollen. This inflammation can affect blood vessels of different sizes throughout the body, and depending on which vessels are involved, it can impact organs such as the kidneys, lungs, skin, or nerves. There are actually many different types of vasculitis, and they vary quite a bit in how serious they are and which parts of the body they affect. Doctors typically classify them by the size of the blood vessels involved and the specific patterns of inflammation seen.

In Australia, vasculitis is considered a rare condition, though some forms are more common than others. It can affect people of any age, including children, but certain types tend to appear more often in older adults. Both men and women can be diagnosed, and the rates can differ depending on the specific type of vasculitis. Because it is relatively uncommon, many Australians are managed through specialist rheumatology or immunology clinics, sometimes in larger hospitals or teaching facilities that have more experience with these conditions.

Treatment for vasculitis generally aims to reduce the inflammation and prevent the immune system from continuing to damage blood vessels and organs. This often involves medications that calm or suppress the immune system. The type and length of treatment can vary significantly depending on which type of vasculitis a person has, how severe it is, and which organs are affected. Many people require ongoing monitoring and follow-up appointments with their specialist to check how well treatment is working and to watch for any changes over time.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Vasculitis in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Vasculitis

1 medicine listed on the PBS for Vasculitis. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 1 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Avacopan Tavneos Anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis AU$8323.2 Authority required

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Vasculitis currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Vasculitis.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Vasculitis by country. Australia is highlighted.

Showing the top 10 of 46 countries with trial sites.

Clinical trials for Vasculitis

Showing 149 of 149 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00987389 · University of Pennsylvania Phase 3 · 15 countries Completed
Completed Phase 3 Est. completion 1 August 2017
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇩🇰 DK🇫🇷 FR🇬🇷 GR🇮🇹 IT +7 more

**Who might be able to join this trial:** - You have been diagnosed (either recently or in the past) with a condition called granulomatosis with polyangiitis or microscopic polyangiitis (two types of blood vessel inflammation) - You have had a positive blood test for specific antibodies linked to these conditions (call...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01663623 · Human Genome Sciences Inc., a GSK Company Phase 3 · 20 countries Completed
Completed Phase 3 Est. completion 6 February 2017
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇭🇺 HU🇮🇪 IE +12 more

Who might be able to join this trial: - You have been diagnosed with Wegener's granulomatosis (also called GPA) or microscopic polyangiitis using standard medical criteria. - Your condition had a flare-up in the past 26 weeks that required treatment with high-dose steroids and one of the following medicines: rituximab,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01697267 · Cambridge University Hospitals NHS Foundation Trust Phase 3 · 10 countries Completed
Completed Phase 3 Est. completion 22 November 2018
🇦🇺 AU🇨🇦 CA🇨🇿 CZ🇮🇪 IE🇮🇹 IT🇯🇵 JP🇳🇿 NZ🇸🇪 SE +2 more

**Who might be able to join this trial:** - You have been diagnosed with a specific type of vasculitis (blood vessel inflammation) called granulomatosis with polyangiitis or microscopic polyangiitis. - A blood test has shown (now or in the past) the presence of certain antibodies linked to this condition, called PR3 o...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03725202 · AbbVie Phase 3 · 24 countries Completed
Completed Phase 3 Est. completion 6 February 2024
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇩🇰 DK🇫🇷 FR🇩🇪 DE +16 more

**Who might be able to join this trial:** - You have been diagnosed with giant cell arteritis (GCA), confirmed by blood tests showing high inflammation levels, plus symptoms of GCA or a related condition called polymyalgia rheumatica, AND confirmed by a biopsy or a scan (such as ultrasound, MRI, CT, or PET). - Your GC...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03827018 · Kiniksa Pharmaceuticals, Ltd. Phase 2 · 15 countries Completed
Completed Phase 2 Est. completion 13 August 2020
🇦🇺 AU🇧🇪 BE🇭🇷 HR🇪🇪 EE🇩🇪 DE🇮🇪 IE🇮🇹 IT🇳🇱 NL +7 more

**Who might be able to join this trial:** - You have been diagnosed with Giant Cell Arteritis (GCA) that is either newly diagnosed or has come back or not responded to previous treatment. - Your blood tests show signs of inflammation — specifically, a high erythrocyte sedimentation rate (above 30 mm/hour) or elevated...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06733935 · Nkarta, Inc. Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 October 2028
🇦🇺 AU Puerto Rico🇺🇸 US

**Who might be able to join this trial:** **General requirements (all participants):** - People aged 18 to 75 years old - People who are willing and able to sign a consent form and follow the study schedule and requirements - Women who could become pregnant must have a negative pregnancy test at the start of the study...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07160608 · Alexion Pharmaceuticals, Inc. Phase 2 · 14 countries Recruiting
Recruiting Phase 2 Est. completion 11 October 2027
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇮🇹 IT +6 more

**Who might be able to join this trial:** - People who have been newly diagnosed with, or are experiencing a return of, a condition called ANCA-associated vasculitis (specifically the GPA or MPA types), and whose doctors are considering treatment with rituximab or cyclophosphamide. - People who have tested positive fo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02531633 · GlaxoSmithKline Phase 3 · 13 countries Terminated
Terminated Phase 3 Est. completion 21 March 2018
🇦🇺 AU🇧🇪 BE🇧🇬 BG🇫🇷 FR🇩🇪 DE🇭🇺 HU🇮🇹 IT🇳🇱 NL +5 more

**Who might be able to join this trial:** - You are 50 years of age or older - You have been diagnosed with Giant Cell Arteritis (GCA), confirmed by specific blood test results showing signs of inflammation (confirm with trial site for exact values) - You have had at least one key symptom of GCA, such as head or scalp...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03600805 · Sanofi Phase 3 · 21 countries Terminated
Terminated Phase 3 Est. completion 24 November 2020
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇨🇦 CA🇭🇷 HR🇩🇰 DK🇪🇪 EE🇫🇷 FR +13 more

**Who might be able to join this trial:** - You have been diagnosed with Giant Cell Arteritis (GCA) according to recognised medical classification standards - Your GCA is either newly diagnosed or has not responded well to previous treatment - You have had at least one symptom of GCA within the past 6 weeks before the...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00315380 · University of Pennsylvania Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇨🇦 CA🇩🇪 DE🇮🇹 IT🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with eosinophilic granulomatosis with polyangiitis (a rare condition that causes inflammation of the blood vessels) may be considered for this trial. - If the person joining is a child or someone who cannot consent for themselves, a parent or gu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02257866 · National Institute of Arthritis and Musculoskeletal and Skin Diseases... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2050
🇺🇸 US

Who might be able to join this trial: **People with vasculitis (inflammation of blood vessels):** - People who have been diagnosed with certain types of vasculitis, including GPA, PAN, EGPA, GCA, TAK, or MPA, based on recognised medical classification systems - People with other suspected forms of vasculitis affecting...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02280733 · U.S. Wound Registry Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇺🇸 US

**Who might be able to join this trial:** - You have one or more long-lasting wounds or sores that have not fully healed, regardless of what caused them - Your wound is being treated at a clinic, hospital, doctor's office, at home, or another care setting that is part of this study - Your wound care records are kept us...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02638701 · University of California, San Francisco Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2028
🇺🇸 US

Who might be able to join this trial: - People who have a specific type of enlarged, widened artery (called a dolichoectatic aneurysm) in the back part of the brain that cannot be treated with surgery or other standard procedures. - People who are older than 18 years of age at the time the study treatment begins. Who...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02939573 · University of Pennsylvania Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇨🇦 CA🇯🇵 JP🇺🇸 US

Who might be able to join this trial: - People aged 18 or older who have been diagnosed with a form of vasculitis that is limited to the skin, such as isolated cutaneous small or medium vessel vasculitis, cutaneous polyarteritis nodosa, or IgA vasculitis (previously called Henoch-Schönlein purpura) without significant...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02964364 · Aimin Dang Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - Your symptoms of Takayasu arteritis started before you were 40 years old - You experience tiredness, pain, or discomfort in the muscles of one or more limbs during activity, especially in the arms - You have a weak or reduced pulse in one or both arms (in the upper arm area)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02967068 · University of Pennsylvania Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇨🇦 CA🇺🇸 US

Who might be able to join this trial: - You are currently enrolled in, or have previously been enrolled in, one of the related VCRC (Vasculitis Clinical Research Consortium) research studies listed in their program (confirm with trial site for the specific study numbers that apply to you). Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03004326 · Peter Merkel Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You have a skin lesion (such as spots, raised rashes, sores, bumps, or hives) that doctors believe is related to active vasculitis (inflammation of the blood vessels) - You have a suspected or confirmed diagnosis of one of the following conditions: Cryoglobulinemic vasculitis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03290456 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 October 2029
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with a condition called MPA (microscopic polyangiitis) or GPA (granulomatosis with polyangiitis), regardless of their ANCA blood test result - People aged 18 years or older - People whose condition is either newly diagnosed or has come back afte...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03372980 · Beijing Institute of Heart, Lung and Blood Vessel Diseases Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: **Retrospective (past medical records) group:** - People who were first diagnosed with or showed symptoms of Takayasu arteritis at age 40 or younger - People who experienced pain, weakness, or cramping in their arms or legs due to reduced blood flow - People who had weak or absent...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03647852 · Children's Hospital of Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 February 2026
🇨🇳 CN

Who might be able to join this trial: - Children or adolescents between 2 and 16 years old (any gender) - People diagnosed with IgA vasculitis (a condition where the immune system causes inflammation in small blood vessels) that affects the digestive system - People whose illness has been ongoing for less than 2 months...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04006535 · Benjamin Terrier Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2029
🇫🇷 FR

**Who might be able to join this trial:** *If you have vasculitis:* - You can be any age (children and adults are welcome) - You have been diagnosed with vasculitis according to a standard international classification system - You are willing to read information about the study and sign a consent form agreeing to take...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04012905 · University Hospital, Caen Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 3 May 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are 50 years of age or older - You have been diagnosed with giant cell arteritis (a condition affecting certain arteries) and meet at least 2 out of 4 specific criteria set by the American College of Rheumatology - Your diagnosis was confirmed by at least one of the follo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04102930 · University of Leeds Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2028
🇬🇧 GB

Who might be able to join this trial: - You are willing to identify which ethnic group you belong to (for example, Caucasian, Asian, or Afro-Caribbean). - You have been diagnosed with Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR), or if you are being assessed now, your doctor believes GCA or PMR is the mos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04278404 · Duke University Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You are under 21 years of age - A parent, legal guardian, or the participant themselves (if an adult) understands and is willing to sign a consent form agreeing to take part - Either you are currently taking one or more of the specific medications being studied, OR you are no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04300686 · Shanghai Zhongshan Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 May 2022
🇨🇳 CN

**Who might be able to join this trial:** - People aged 14 years or older - People with an active condition, shown by a Kerr score of 2 or higher (a measure of disease activity — confirm with trial site) - People with a severe form of the condition, meeting at least one of the following: very high blood pressure (above...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04413331 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years old or older - You must have been diagnosed with vasculitis (a condition involving inflammation of the blood vessels), as defined by an internationally recognised classification updated in 2012 - You must be experiencing an active phase of the disease, either...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04538937 · Medical University Innsbruck Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 February 2021
🇦🇹 AT

Who might be able to join this trial: - You are 18 years old or older - You have had a blood test showing a high number of eosinophils (a type of white blood cell) — specifically 300 or more per microlitre of blood - You have confirmed damage to your airways or lungs that has been caused by these eosinophil cells Who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04656184 · Assistance Publique - Hôpitaux de Paris Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 March 2027
🇫🇷 FR

**Who might be able to join this trial:** - Children (both boys and girls) between 3 months and under 18 years of age - Children who weigh at least 5 kg (about 11 pounds) - Children diagnosed with Kawasaki Disease (KD) — either the full or incomplete form — based on American Heart Association guidelines, which include...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04871191 · Assistance Publique - Hôpitaux de Paris Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2028
🇫🇷 FR

**Who might be able to join this trial:** - You have been newly diagnosed with, or are experiencing a relapse of, a condition called granulomatosis with polyangiitis (GPA), confirmed using recognised medical guidelines - You are 18 years old or older - You currently have active symptoms caused by GPA - Your GPA has no...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04919538 · University of Pennsylvania Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a condition called relapsing polychondritis, as determined by the doctor running the trial. Who may not be able to join: - You are unable to give your own consent to take part in the trial (or, if you are a minor/child, you are unable to give your ag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05003986 · Travere Therapeutics, Inc. Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 12 March 2027
🇩🇪 DE🇮🇹 IT🇳🇱 NL🇵🇱 PL🇪🇸 ES🇸🇪 SE🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** **Criteria that apply to all groups:** - The person (or their parent or legal guardian, if appropriate) is willing and able to sign a consent form before any screening tests take place. - The person's kidneys are functioning at a level of 30 or above on a standard kidney funct...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05012033 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇬🇧 GB

**Who might be able to join this trial:** - You are between 18 and 75 years old - You are male or female - You are generally healthy enough to take part, based on your medical history - You are able and willing to sign a written consent form to join the study - **(Group A only)** You need a short course (less than 5 d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05102448 · Shanghai Zhongshan Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Takayasu Arteritis (TAK) using recognized medical classification guidelines - You are a man or woman between 18 and 65 years old - You agree not to try to become pregnant (or father a child) during the trial, and if you are a woman, your pregnanc...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05251415 · University Hospital, Toulouse Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 April 2027
🇫🇷 FR

Who might be able to join this trial: - You have been diagnosed with a rare autoimmune disease that affects the whole body, such as lupus, scleroderma, or myositis - You have an unusual or hard-to-diagnose form of a known or suspected autoimmune disease - You are currently receiving, or are expected to receive, a newer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05315141 · Xiangya Hospital of Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 16 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with ANCA-associated vasculitis according to the 2012 medical classification criteria for this condition, and who are willing to sign a consent form agreeing to take part in the study. **Who may not be able to join:** - People who are not willi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05383339 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 November 2031
🇫🇷 FR

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with one of the following conditions, confirmed using recognised international medical standards: - A connective tissue disease such as lupus, Sjögren's syndrome, antiphospholipid syndrome, Sharp syndrome, scleroderma, or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05435781 · Marianne Christina Klose Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 June 2026
🇩🇰 DK

**Who might be able to join this trial:** - You are 50 years of age or older - If you are a woman, you must be past menopause (this will be checked with a blood test at your first visit) - You have been diagnosed with polymyalgia rheumatica (PMR), giant cell arteritis (GCA), or both conditions together - You have been...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05437965 · China National Center for Cardiovascular Diseases Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2035
🇨🇳 CN

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with a specific condition called RECUR, which involves repeated, unexplained narrowing returning inside a coronary stent (a small tube placed in a heart artery) - You have been fully informed about what the trial involves an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05479448 · University Hospital, Basel, Switzerland Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇨🇭 CH

Who might be able to join this trial: - You have been diagnosed with Polymyalgia Rheumatica (PMR) or Giant Cell Arteritis (GCA) based on recognized medical diagnostic guidelines - You agree to have your health information included in the SCQM database (a Swiss medical registry for rheumatic diseases) - You are willing...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05565885 · University Hospital, Tours Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2037
🇫🇷 FR

**Who might be able to join this trial:** - You are older than 16 years of age - You have active vasculitis (inflammation of the blood vessels) that is either newly diagnosed or has come back after a period of improvement - You have been diagnosed with IgA vasculitis (a type of blood vessel inflammation linked to a pro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05628948 · The Cleveland Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You are able to understand and sign a consent form agreeing to take part in the study - You have been diagnosed with, or are considered at risk for, heart or metabolic diseases (such as diabetes or obesity) Who may not be able to join: - You ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05643651 · Children's Hospital of Fudan University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 June 2027
🇨🇳 CN

Who might be able to join this trial: - Children aged 2 years or older who have developed large coronary artery aneurysms (abnormal bulges in the heart's blood vessels) following the active stage of Kawasaki disease, confirmed by ultrasound imaging and meeting specific size measurements - Children for whom doctors reco...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05734404 · University of Pennsylvania Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Central Nervous System Vasculitis (CNSV), meaning you have developed new, unexplained neurological symptoms (such as problems with thinking, movement, or sensation) that cannot be explained by another cause - Your diagnosis has been confirmed eith...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05854615 · Cell Biopeutics Resources Sdn Bhd Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 October 2027
🇲🇾 MY

Who might be able to join this trial: - You are a man or woman aged between 18 and 65 years old, and if you could become pregnant, you are willing to use an accepted form of birth control during the study - You have been diagnosed with Buerger's disease (a condition affecting blood vessels) using a specific set of reco...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05854927 · Fondation Ophtalmologique Adolphe de Rothschild Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years of age or older - You have been referred for an MRI scan with contrast dye (an injected MRI) because giant cell arteritis (GCA) is suspected - Your doctors suspect you may have GCA based on a combination of signs — either three "major" signs or two "major" pl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05865054 · University of Pennsylvania Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 July 2030
🇨🇦 CA🇩🇪 DE🇺🇸 US

**Who might be able to join this trial:** - You are 50 years old or older - This is the first time you are being assessed for a condition called Giant Cell Arteritis (GCA) - You have developed new or worsening symptoms affecting your head or face (such as headaches or jaw pain) within the last 4 weeks that may be relat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05934149 · Lupus Research Alliance Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2035
🇨🇦 CA🇺🇸 US

Who might be able to join this trial: - People who are able to understand the study procedures and are willing to sign a consent form agreeing to take part - People who are 18 years of age or older at the time of joining the trial - People who have been diagnosed with Systemic Lupus Erythematosus (SLE, a type of autoim...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05935709 · Aarhus University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2034
🇩🇰 DK

Who might be able to join this trial: - You have been diagnosed with Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR) within the last 5 years - Your diagnosis has been made or confirmed by a rheumatologist (a specialist in joint and immune system conditions) - You can speak and understand Danish - You are abl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05937880 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - Children and teenagers between 1 and 18 years old - Patients who have been diagnosed with HSP (Henoch-Schönlein Purpura, a condition that causes a skin rash and can affect the joints, gut, and kidneys) - Patients whose skin rash from HSP is severe (widespread and dense) and h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05946564 · Assistance Publique - Hôpitaux de Paris Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 24 April 2028
🇫🇷 FR

**Who might be able to join this trial:** - You have been newly diagnosed with, or are experiencing a return of, a condition called ANCA-associated vasculitis — specifically granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) — and your disease is currently active (confirm with trial site) - Your...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05951517 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - Children and teenagers between 3 and 18 years old - Patients who have been diagnosed with Henoch-Schönlein Purpura (HSP) — a condition that affects the blood vessels — and are experiencing digestive system symptoms such as severe stomach cramping, a bowel blockage, or bleedin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05962840 · Chinese SLE Treatment And Research Group Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old (any gender) - You have been newly diagnosed with, or are experiencing a return of, a condition called granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), confirmed using recognized medical classification standards - Y...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05965284 · Chinese SLE Treatment And Research Group Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - You are between 18 and 65 years old (any gender). - You have been diagnosed with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), either for the first time or as a returning condition, meeting specific medical classification standards. - Your disease is c...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05979051 · Guangdong Hengrui Pharmaceutical Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2028
🇨🇳 CN

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with a condition called EGPA (a type of inflammatory disease affecting blood vessels) for at least 6 months - Your EGPA has come back after treatment or has not responded well to treatment - You have been taking oral pred...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06004154 · Fondation Ophtalmologique Adolphe de Rothschild Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇫🇷 FR

**Who might be able to join this trial:** - You are 50 years old or older - You have given your written agreement (consent) to take part in the study - You are covered by a social insurance or health coverage scheme - You have been diagnosed with giant cell arteritis (a condition causing inflammation of blood vessel wa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06047171 · Alentis Therapeutics AG Phase 2 · 10 countries Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇨🇿 CZ🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇹 IT🇪🇸 ES🇸🇪 SE🇨🇭 CH +2 more

**Who might be able to join this trial:** - Adults aged 18 or older of any race or ethnicity who have been assessed as not frail (below a score of 7 on a standard frailty scale) in the 3 months before developing the kidney condition being studied, which is a rapidly worsening kidney disease (RPGN) linked to a conditio...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06056921 · Chongqing Precision Biotech Co., Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with one of the following conditions: Systemic Lupus Erythematosus (SLE), Sjögren's Syndrome, Systemic Scleroderma, Dermatomyositis (with a specific positive antibody test result), or a type of blood vessel inflammation...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06065852 · UK Kidney Association Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2039
🇬🇧 GB

Who might be able to join this trial: - People (both children and adults) who have a rare kidney disease - Eligibility depends on which specific rare kidney disease you have, so requirements will vary from person to person (confirm with trial site) Who may not be able to join: - People whose specific rare kidney disea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06072482 · Amgen Phase 4 · 7 countries Recruiting
Recruiting Phase 4 Est. completion 31 December 2036
🇨🇿 CZ🇩🇰 DK🇬🇷 GR🇭🇺 HU🇵🇱 PL🇷🇴 RO🇺🇸 US

**Who might be able to join this trial:** - People who have given written consent before any study-related activities begin. - People who have been newly diagnosed with, or have experienced a relapse of, granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), where a doctor has determined that treatm...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06107361 · Corewell Health East Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇺🇸 US

**Who might be able to join this trial:** *(For patients/study participants:)* - You are 18 years old or older - Your veins are difficult to access — either they can be seen but are hard to feel, or they cannot be seen or felt easily (this is called a Vascular Access Score of 4 or 5; confirm with trial site if unsure...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06178419 · Xuanwu Hospital, Beijing Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Takayasu Arteritis (TAK) according to specific established medical criteria - Your disease is currently in an inactive (not flaring) state - You are male or female, aged between 18 and 65 years old - Your condition affects the large blood vessels...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06271018 · Groupe français d'étude des Maladies Inflammatoires de loeil Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 September 2026
🇫🇷 FR

Who might be able to join this trial: - You are 18 years old or older - You are willing and able to sign a consent form agreeing to take part in the trial - You are covered by the French national social security system - You are using effective birth control methods - If you are a woman who could become pregnant, you h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06277427 · Lingli Dong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 70 years old (70 is included) - If your kidneys are affected, they must still be working at a minimum level as measured by a specific kidney function test (eGFR ≥ 15 mL/min/1.73m²) - Your recent blood test results meet certain minimum levels for white...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06279065 · University of Bonn Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 February 2026
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with Giant cell arteritis (this applies to one specific group within the trial) **Who may not be able to join:** - You have a long-term (chronic) infection, such as a viral, fungal, or bacterial infection, including HIV or Hepatitis B or C - You have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06285279 · Nanjing University School of Medicine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have personally signed a consent form approved by the Ethics Committee before the study begins - People aged 18 to 65 years old - People with one of the following kidney or immune conditions (see details below): **Lupus Nephritis (LN):** People with an active,...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06298448 · University Medical Center Groningen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇳🇱 NL

**Who might be able to join this trial:** - People who are 18 years of age or older - People who are able to give informed consent (meaning they can understand and agree to take part) - People in the chronic sinusitis with nasal polyps group: those who have been diagnosed with nasal polyps in both nostrils, confirmed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06305611 · Meyer Children's Hospital IRCCS Not Applicable · 11 countries Recruiting
Recruiting Not Applicable Est. completion 15 July 2026
🇧🇷 BR🇭🇷 HR🇫🇷 FR🇮🇳 IN🇮🇱 IL🇮🇹 IT🇳🇱 NL🇪🇸 ES +3 more

Who might be able to join this trial: - You were younger than 18 years old when you were diagnosed - You have been diagnosed with Kawasaki Disease (KD) based on the American Heart Association (AHA) guidelines Who may not be able to join: - You do not have a confirmed diagnosis of Kawasaki Disease - Other possible infe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06308978 · Fate Therapeutics Phase 1 · 4 countries Recruiting
Recruiting Phase 1 Est. completion 30 September 2027
🇫🇷 FR🇸🇪 SE🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You are between 12 and 70 years old. - You have been diagnosed with an active B-cell related autoimmune disease, specifically lupus (SLE), a type of blood vessel inflammation (AAV), inflammatory muscle disease (IIM), or systemic sclerosis (SSc), confirmed by standard medical...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06335888 · Insel Gruppe AG, University Hospital Bern Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2029
🇨🇭 CH

**Who might be able to join this trial:** - You are 50 years old or older and your doctor suspects you may have Giant Cell Arteritis (GCA), a condition causing inflammation of the arteries - If you are a woman who could become pregnant, you must have a negative pregnancy blood test at the first visit - You are able to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06350110 · Essen Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 90 years old. - People who have been classified as having Systemic Lupus Erythematosus (SLE) based on a recognised scoring system (EULAR/ACR 2019 criteria), with a total score of 10 or higher. - People whose lupus disease activity score (SELENA-SLEDAI) is 8...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06379646 · China Immunotech (Beijing) Biotechnology Co., Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 April 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 65 years old (any gender). - People whose blood tests show a protein called CD19 is present on their B cells (a type of immune cell), confirmed by a specific lab test. - People whose bone marrow, liver, kidneys, blood clotting, and heart are functioning at...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06417502 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2024
🇨🇳 CN

Who might be able to join this trial: - People who are 18 years old or younger - People who have been diagnosed with a rheumatic or immunologic disease (such as conditions affecting the connective tissue, joints, blood vessels, or the immune system from birth) - People who have been diagnosed and are receiving treatmen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06460142 · University of Bonn Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇩🇪 DE

**Who might be able to join this trial:** - You must be over 18 years old and willing to sign a consent form agreeing to take part in the study. - You must have a confirmed diagnosis of Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR), confirmed by your doctor using recognised medical classification standards...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06462768 · CHU de Reims Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 October 2028
🇫🇷 FR

**Who might be able to join this trial:** *Group 1 – Systemic Sclerosis patients:* - You have been diagnosed with a condition called systemic sclerosis (a type of autoimmune disease affecting the skin and internal organs), confirmed using recognised medical criteria - You are currently being treated in the internal me...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06498089 · Shanghai Zhongshan Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with aortitis (inflammation of the main artery from the heart) according to 2022 medical classification standards - You are a woman or man between 18 and 65 years old - Your disease is currently active, based on a specific scoring system called the NI...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06500728 · ASST Fatebenefratelli Sacco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇮🇹 IT

**Who might be able to join this trial:** - You are over 18 years old and have been diagnosed with, or are suspected to have, giant cell arteritis (a condition where the immune system causes inflammation in the blood vessels). - You have recently developed vision problems that are thought to be linked to inflammation...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06512883 · AstraZeneca Phase 3 · 10 countries Recruiting
Recruiting Phase 3 Est. completion 20 February 2028
🇧🇷 BR🇨🇦 CA🇫🇷 FR🇮🇳 IN🇮🇱 IL🇲🇽 MX🇳🇱 NL🇵🇱 PL +2 more

**Who might be able to join this trial:** **All participants:** - Children and teenagers between 6 and under 18 years old at the time of signing the study forms (with a caregiver also signing on their behalf) - Participants must weigh at least 15 kilograms (about 33 pounds) **For the EGPA group specifically:** - Part...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06548607 · Nanjing Bioheng Biotech Co., Ltd. Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have voluntarily agreed to take part and have signed a consent form - People aged between 18 and 70 years old (any sex) - People whose liver function blood test results are within an acceptable range (confirm with trial site) - People whose kidney function test re...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06581562 · IRIS Research and Development, LLC Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who are able to understand what the study involves and are willing to follow the study procedures and sign a consent form. - People who are able to use two forms of contraception together throughout the study (examples include hormonal birth control,...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06593041 · University Hospital, Strasbourg, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 February 2027
🇫🇷 FR

**Who might be able to join this trial:** - You are between 18 and 70 years old - You are covered by a health insurance plan (either as the main member or as a dependant) - You are able to understand the goals and potential risks of the research - You have signed and dated a consent form agreeing to take part - You hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06599411 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 November 2035
🇫🇷 FR

**Who might be able to join this trial:** *If you have a skin condition:* - You are over 18 years old - You have given your written agreement to take part in the trial - You have been diagnosed with a moderate to severe long-term inflammatory skin condition (this includes: atopic dermatitis, psoriasis, hidradenitis su...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06611696 · Chiba University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 March 2027
🇯🇵 JP

**Who might be able to join this trial:** - You are 18 years old or older - You have been recently diagnosed with a condition called ANCA-associated vasculitis (specifically granulomatosis with polyangiitis or microscopic polyangiitis), based on recognised medical definitions - You have had a positive blood test showin...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06614270 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 January 2026
🇨🇳 CN

**Who might be able to join this trial:** **General requirements (all conditions):** - Adults between 18 and 65 years old, of any gender - Blood cell counts within acceptable ranges — enough red blood cells, white blood cells, and infection-fighting cells (neutrophils), without having received certain blood-boosting m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06642870 · University of the West of England Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇬🇧 GB

Who might be able to join this trial: - You have been diagnosed with a rare rheumatic condition by a hospital doctor or specialist, such as lupus, systemic vasculitis, myositis, or Sjögren's syndrome - You are able to agree to take part in the study (translation help can be provided if English is not your first languag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06676384 · Christian Medical College, Vellore, India Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 August 2029
🇮🇳 IN

**Who might be able to join this trial:** - People who are able to give written consent before any study assessments begin - Adults aged 18 to 65 years, of any sex - People who have been diagnosed with primary IgA nephropathy (a kidney condition), confirmed by a kidney biopsy — the timing requirements for how recent t...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06685042 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇮🇹 IT

**Who might be able to join this trial:** - People who are able to understand the trial and are willing to sign a consent form, including agreeing to how their data will be used - Adults who are 18 years of age or older and under 65 years of age at the time of signing consent - Male participants who are not surgically...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06698614 · University of Edinburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 November 2029
🇬🇧 GB

**Who might be able to join this trial:** - You are able to give written agreement to take part after being fully informed about the study - You are over 18 years old - You are able to attend all required study visits - If you are female, you are not pregnant (confirmed by a negative pregnancy test), or you have gone...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06742671 · Groupe Hospitalier de la Rochelle Ré Aunis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇫🇷 FR

Who might be able to join this trial: - You are being assessed by doctors who suspect you may have Giant Cell Arteritis (GCA), a condition involving inflammation of the blood vessels (confirm with trial site) Who may not be able to join: - You do not want your personal data to be used as part of this study Important:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06758271 · Kissei Pharmaceutical Co., Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2028
🇯🇵 JP

Who might be able to join this trial: - You have been diagnosed with granulomatosis with polyangiitis or microscopic polyangiitis (these are types of rare inflammatory conditions that affect the blood vessels) - You are currently being treated with a medication called avacopan Who may not be able to join: - No specifi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06770374 · Hospital Arnau de Vilanova Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇪🇸 ES

Who might be able to join this trial: - People who need a midline catheter or a PICC (a type of thin tube inserted into a vein to deliver medications or fluids) placed during their hospital stay - People who have agreed to take part and have signed the consent form voluntarily - People who are admitted to hospital for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06775457 · IRCCS Azienda Ospedaliero-Universitaria di Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇮🇹 IT

Who might be able to join this trial: - Children who have recently been diagnosed with Kawasaki disease (a condition that causes inflammation in blood vessels) - Children who have recently been diagnosed with Vasculitis (inflammation of the blood vessels) - Children who have recently been diagnosed with a SARS-CoV-2 in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06775912 · Nanjing Bioheng Biotech Co., Ltd. Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 January 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have agreed to take part voluntarily and have signed a consent form - People aged 18 to 70 years old (any sex) - People whose liver is working within acceptable ranges on blood tests (confirm with trial site for specific values) - People whose kidneys are working...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06779799 · University Hospital, Brest Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2025
🇫🇷 FR

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with a systemic autoimmune disease, such as rheumatoid arthritis, lupus, systemic sclerosis, primary Sjögren's disease, sarcoidosis, vasculitis, myositis, Still's disease, or Sharp syndrome - You are experiencing voice probl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06794827 · Leiden University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇳🇱 NL

**Who might be able to join this trial:** - You have been diagnosed with a condition called GPA (Granulomatosis with Polyangiitis) or MPA (Microscopic Polyangiitis), which are types of blood vessel inflammation diseases - You are being treated with, or are starting treatment with, a medication called avacopan - You agr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06824714 · Nanjing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have been suspected of having or confirmed to have large vessel vasculitis (a condition where the body's large blood vessels become inflamed), and you are willing to have a PET/MRA scan (a type of imaging scan that combines two scanning methods) - You are willing and able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06828042 · Peking University Third Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 80 years old (male or female). - People whose blood tests show a protein called CD19 is present on certain immune cells (B cells). - People diagnosed with a refractory autoimmune disease — meaning standard treatments have not worked for more than 6 mont...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06866535 · University Hospital, Bordeaux Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 May 2032
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years old or older - You have been diagnosed with an infection affecting a blood vessel, either in a natural blood vessel (such as an infected artery or aorta) or in an artificial one (such as a surgically implanted graft, stent, or similar device) - You are able t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06868290 · Novartis Pharmaceuticals Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 7 June 2029
🇧🇷 BR🇮🇱 IL🇯🇵 JP🇸🇦 SA🇸🇬 SG🇨🇭 CH🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 75 years old who have been diagnosed with a condition called GPA (Granulomatosis with Polyangiitis) or MPA (Microscopic Polyangiitis), based on recognised 2022 medical classification guidelines - People who have tested positive for specific proteins in t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06887062 · University of Edinburgh Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with a condition called large vessel vasculitis (a disease that causes inflammation in large blood vessels) and it has been in remission (not active) for at least 6 months. **Who may not be able to join:** - You are under 18 years old - Your large ves...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06923072 · National Heart, Lung, and Blood Institute (NHLBI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 14 December 2030
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to sign a consent form, or have someone legally authorized to sign on your behalf. - You are willing to follow all study procedures and be available for the full duration of the study. - You are male or female, aged 18 or older. - You have been diagno...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06940661 · Assistance Publique - Hôpitaux de Paris Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with a relapsing (returning) condition called granulomatosis with polyangiitis (GPA), confirmed by recognised medical classification systems, and a specific blood marker called PR3-ANCA is present at the time of joining...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06941129 · Institute of Hematology & Blood Diseases Hospital, China Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 18 February 2028
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender. - People whose blood tests (flow cytometry) show the presence of specific proteins called CD19 or BCMA on their B cells (a type of immune cell). - People whose bone marrow, liver, and kidney functions meet certain minimum levels as mea...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06941376 · University of Pennsylvania Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with Relapsing Polychondritis (RP) based on one of three recognized sets of diagnostic criteria involving symptoms such as inflammation of the ears, nose, airways, eyes, or joints, and/or problems with hearing or bal...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06978439 · Children's Hospital of Fudan University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with large balloon-like bulges (called giant aneurysms) in one or more of the heart's blood vessels following Kawasaki disease, confirmed by heart ultrasound with specific measurements meeting set thresholds - Your doctors recommend taking a combination of...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06978647 · China Immunotech (Beijing) Biotechnology Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 19 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 65 years old (any gender) may be considered. - People whose blood tests show a protein called CD19 is present on certain immune cells (B cells), confirmed by a laboratory test called flow cytometry. - People whose bone marrow is functioning well enough, sho...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06980597 · Beijing GoBroad Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** **General requirements:** - Adults between 18 and 65 years old - Reasonably good general health and ability to carry out daily activities, as measured by a standard medical scale (ECOG score of 0–2) - Kidneys, liver, and other organs are functioning at an adequate level - Wom...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06983028 · Vera Therapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2027
🇺🇸 US

**Who might be able to join this trial:** - You weigh at least 40 kg (about 88 pounds) - You are currently on a stable, prescribed treatment plan for your kidney condition, following local medical guidelines - Your blood pressure at your screening visit is not too high (top number no more than 160, bottom number no mo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06983821 · Ottawa Hospital Research Institute Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2028
🇨🇦 CA

**Who might be able to join this trial:** - You have been recently diagnosed with, or have had a return of, a condition called granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) - A specific blood test (ELISA) has come back positive for certain markers linked to these conditions (called MPO or PR...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06993636 · Children's Hospital of Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Children aged 2 years old up to (but not including) 18 years old - Children who have developed large balloon-like bulges (called giant aneurysms) in the blood vessels of the heart following Kawasaki disease, confirmed by a specific heart ultrasound test showing the bulge meet...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07010250 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 November 2029
🇫🇷 FR

**Who might be able to join this trial:** - You need to be having your first-ever diagnostic biopsy (a small tissue sample taken from the kidney) on your own natural kidney - You must be between 18 and 90 years old - You must be covered by French health insurance - You must have agreed and given your consent to take pa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07024563 · Alexion Pharmaceuticals, Inc. Phase 3 · 7 countries Recruiting
Recruiting Phase 3 Est. completion 12 July 2028
🇨🇳 CN🇮🇹 IT🇯🇵 JP🇰🇷 KR🇪🇸 ES🇹🇼 TW🇺🇸 US

**Who might be able to join this trial:** - You must be between 2 and 17 years old at the time of signing the consent forms - You must have been on a stable, maximum-tolerated dose of certain blood pressure/kidney-protecting medications (called RASI, such as ACE inhibitors or ARBs) for at least 3 months before the scr...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07037732 · Centre Hospitalier Universitaire de Nice Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇫🇷 FR

"Who might be able to join this trial: - You are already receiving a medication called rituximab as part of your normal medical care (not as part of a study). - You have been diagnosed with one of the following conditions: a blood platelet disorder called immune thrombocytopenia, a condition where the immune system des...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07084480 · Wuerzburg University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2030
🇩🇪 DE

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with either Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR) as your main condition Who may not be able to join: - You are under 18 years old - You are not able to give your own consent to take part in the trial (...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07086989 · Semmelweis University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2029
🇭🇺 HU

**Who might be able to join this trial:** - You are between 6 and 25 years old - You have been diagnosed with a long-term childhood health condition that is known to increase the risk of developing heart disease at an early age (confirm with trial site for whether your specific condition qualifies) - You are aged 18 or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07089121 · Cartesian Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are at least 12 years old - You have been officially diagnosed with one of the following conditions: childhood-onset lupus (systemic lupus erythematosus), juvenile Myasthenia gravis, juvenile dermatomyositis, or AAV (confirm with trial site for full name) - Your condition...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07104721 · China Immunotech (Beijing) Biotechnology Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 4 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 65 years old (inclusive), of any gender - People whose bone marrow, liver, kidneys, blood clotting, and heart function all meet minimum health thresholds set by the trial (confirm specific values with trial site) - People who are able and willing to use...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07108387 · National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 11 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to sign a consent form and follow the study's requirements - You have been diagnosed with Giant Cell Arteritis (GCA), a condition affecting the blood vessels, confirmed by at least one symptom (such as new headaches, scalp or jaw pain, vision loss, o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07151521 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇨🇳 CN

Who might be able to join this trial: - You must be 18 years of age or older - You must have been diagnosed with a condition called ANCA-associated vasculitis, based on recognized 2022 medical guidelines - You must also have a lung condition called interstitial lung disease, confirmed by a specialised type of chest sca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07168161 · Staidson (Beijing) Biopharmaceuticals Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 16 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (male or female) - You have been diagnosed with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) — these are conditions where the immune system attacks blood vessels - You have been newly diagnosed or have had a retu...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07203404 · Nanjing Bioheng Biotech Co., Ltd. Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 23 July 2027
🇨🇳 CN

**Who might be able to join this trial:** **General requirements for all participants:** - People who are willing and able to sign a written consent form agreeing to take part - People aged 18 to 75 years old - People whose bone marrow is working well enough, shown by blood counts being above certain levels, without h...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07206238 · Rigshospitalet, Denmark Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇩🇰 DK

Who might be able to join this trial: **For the AION group (people with a possible eye condition affecting the optic nerve):** - Doctors suspect you may have a newly developed loss of blood supply to the optic nerve (the nerve connecting your eye to your brain), based on symptoms in one eye such as swelling at the bac...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07215923 · Antidote Therapeutics, Inc Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to sign a consent form before any study activities begin - People aged 23 to 59 years old (inclusive) - People who weigh at least 50 kg at the time of the screening appointment - People with a body mass index (BMI) between 18.5 and 29.9 at the...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07236762 · China Immunotech (Beijing) Biotechnology Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 24 November 2026
🇨🇳 CN

**Who might be able to join this trial:** **General requirements (all participants must meet these):** - People aged 18 to 65 years old, of any gender. - People whose blood, liver, kidney, and heart function meet minimum health levels set by the trial (specific lab test results will be checked by the trial site). - P...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07236801 · China Immunotech (Beijing) Biotechnology Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 13 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old (inclusive), of any gender - Your blood counts meet minimum levels — specifically, your white blood cell count and hemoglobin are above certain thresholds, without recent use of white blood cell boosting injections (confirm with trial site...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07244614 · Groupe français d'étude des Maladies Inflammatoires de loeil Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years old or older - You do not object to taking part in the study - You are using a reliable form of contraception - You have been diagnosed with Behçet's disease according to the internationally recognised criteria (updated in 2013) - Your doctor has recommended...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07246096 · Changhai Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 20 July 2027
🇨🇳 CN

**Who might be able to join this trial:** **General requirements (apply to all conditions):** - Adults between 18 and 70 years old (male or female) - Blood, liver, clotting, and heart test results that fall within the ranges required by the trial (confirm specific values with trial site) - People who are able and will...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07246577 · Vastra Gotaland Region Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2029
🇸🇪 SE

**Who might be able to join this trial:** - You have been referred to a doctor because giant cell arteritis (a condition causing inflammation of the arteries) is suspected but not yet confirmed. - You are able to read, understand, and sign a consent form agreeing to take part in the study. **Who may not be able to joi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07258524 · University of Edinburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇬🇧 GB

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with active AAV (a condition called ANCA-associated vasculitis, which is a disease causing inflammation of blood vessels) **Who may not be able to join:** - You are not able to have a baseline scan within 3 weeks of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07275190 · Fondazione IRCCS Policlinico San Matteo di Pavia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇮🇹 IT

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with EGPA (a condition called Eosinophilic Granulomatosis with Polyangiitis) or HES (Hypereosinophilic Syndrome), both of which involve high levels of a type of white blood cell called eosinophils - You are able to give writ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07278609 · McGill University Health Centre/Research Institute of the McGill Unive... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2028
🇨🇦 CA

**Who might be able to join this trial:** - You are 60 years of age or older - You are currently being seen by a rheumatologist at the MUHC (McGill University Health Centre) for a joint or immune system condition — such as rheumatoid arthritis, psoriatic arthritis, lupus, scleroderma, gout, osteoarthritis, or a similar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07291245 · University of California, San Diego Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** - You have had a fever (either measured or felt) for 3 or more days - At least one measured temperature of 38.0°C (100.4°F) or higher, whether taken at home or in the emergency department - You have one or more of the following signs that can be linked to Kawasaki Disease: a ra...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07301892 · Guang'anmen Hospital of China Academy of Chinese Medical Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with rheumatoid arthritis (a condition where the immune system attacks the joints, causing pain and swelling) for the first time. - You were admitted to the hospital department involved in this study as an inpatient (meaning you stayed overnight or longer)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07305116 · The Children's Hospital of Zhejiang University School of Medicine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2028
🇨🇳 CN

**Who might be able to join this trial:** **General requirements (all conditions):** - Major organ function must meet minimum levels — including blood cell counts, liver function, kidney function (with some exceptions at the doctor's discretion), heart function showing the heart pumps adequately, and oxygen levels of...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07315087 · Institute of Hematology & Blood Diseases Hospital, China Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2029
🇨🇳 CN

**Who might be able to join this trial:** - You must be 18 years of age or older. - Your blood counts and organ function (bone marrow, liver, and kidneys) must meet certain minimum health levels — your doctor can check these with blood tests. - If you could become pregnant, you must have a negative pregnancy test with...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07339540 · Tongji Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 30 October 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 65 years old at the time of signing the consent form. - People with recurring or treatment-resistant **Systemic Lupus Erythematosus (SLE)** who have been diagnosed using recognised criteria, show certain positive antibody results, have already tried glucoco...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07351422 · University of Edinburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 March 2027
🇬🇧 GB

Who might be able to join this trial: **For patients:** - People who are 18 years of age or older - People who have received a formal diagnosis of Takayasu Arteritis (TAK) - People who are based in the UK - People who have the mental capacity and are willing to give their informed consent to take part **For doctors/p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07388277 · Marcela V. Maus, M.D.,Ph.D. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are able and willing to give written consent to participate before any study procedures begin - People who are 18 years of age or older at the time of signing the consent form - People who have been diagnosed with granulomatosis with polyangiitis (GPA) or microsco...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07413341 · Therorna Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who understand what the trial involves and are willing to sign a consent form agreeing to take part. - People aged between 18 and 65 years old (inclusive), of any gender. - People whose B cells (a type of immune cell) test positive for a protein called CD19, as measur...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07491913 · Marmara University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2027
Turkey (Türkiye)

**Who might be able to join this trial:** - People who have been diagnosed with Takayasu arteritis based on the 2022 American College of Rheumatology/EULAR classification criteria - People who have been receiving a biologic medication (specifically a TNF inhibitor or tocilizumab) for at least 3 years - People whose dis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07507201 · The Children's Hospital of Zhejiang University School of Medicine Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2028
🇨🇳 CN

Who might be able to join this trial: - Major organ function must meet minimum levels set by the trial, including bone marrow, liver, kidney, heart, and lung function, based on blood and other tests (confirm specific values with trial site). - Kidney function must generally be at or above a certain level, though peopl...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07526350 · Shanghai Changzheng Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 April 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 65 years (inclusive) at the time of signing consent, of any gender, who are willing and able to follow the study procedures. - People who have been diagnosed with systemic lupus erythematosus (SLE) according to established 2019 classification standards, wit...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07530640 · Children's Hospital of Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - The child has been diagnosed with Kawasaki disease that has led to problems with the coronary arteries (the blood vessels around the heart), and it has been fewer than 20 days since symptoms started — or more than 20 days have passed but the inflammation from Kawasaki disease...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07556484 · Mayo Clinic Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2028
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a specific type of blood vessel inflammation called ANCA-associated vasculitis — either granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), as defined by recognized medical guidelines. - Your blood tests show a positive result fo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07558382 · Marmara University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2035
Turkey (Türkiye)

**Who might be able to join this trial:** - You have been diagnosed with Takayasu arteritis, confirmed using recognised medical diagnostic guidelines (called ACR 1990 or ACR/EULAR 2021 criteria). - You (or your legal guardian/representative, if applicable) are willing and able to follow the study requirements for the f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07586137 · Fondazione IRCCS Policlinico San Matteo di Pavia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 June 2028
🇮🇹 IT

Who might be able to join this trial: - You are willing and able to agree to take part in the trial by giving your consent - You have either been diagnosed with, or your doctor suspects you may have, a condition called Systemic Vasculitis (a disease where the body's immune system causes inflammation in the blood vessel...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07586267 · The Children's Hospital of Zhejiang University School of Medicine Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 May 2029
🇨🇳 CN

**Who might be able to join this trial:** **General requirements for all participants:** - Blood cell counts, liver function, kidney function, heart function, and lung function must meet minimum levels set by the trial (with some exceptions allowed depending on the condition being treated — confirm with trial site) -...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07664228 · Bursa City Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 February 2027
Turkey (Türkiye)

Who might be able to join this trial: - The child has been diagnosed with IgA vasculitis (also known as Henoch-Schönlein purpura) based on recognised medical classification guidelines. - The child is between 2 and 18 years old. - A blood sample can be taken from the child at the time of their diagnosis (the first visit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07664709 · Military Institute od Medicine National Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇵🇱 PL

Who might be able to join this trial: - You are 18 years of age or older (there is no upper age limit) - You have been diagnosed with ANCA-positive vasculitis (a type of blood vessel inflammation linked to specific antibodies) - You may join whether you have just been diagnosed or are already receiving treatment for th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07703618 · Hospital Universitario San Ignacio Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2025
🇨🇴 CO

Who might be able to join this trial: - Adults aged 18 years or older who have had a small plastic tube (called a peripheral IV line) inserted into a vein in their arm or hand within the last 24 hours - People who are expected to need that IV line in place for at least 48 hours Who may not be able to join: - People wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Vasculitis. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

The Australia and New Zealand Vasculitis Society (ANZVASC) is the dedicated body for vasculitis support.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.